Abcam acquires California-based antibodies developer Calico Biolabs
Category: #health  By Nikita Chaurasia  Date: 2019-01-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Abcam acquires California-based antibodies developer Calico Biolabs

U.K. biotech firm Abcam has recently confirmed the acquisition of Calico Biolabs, a specialist in rabbit monoclonal antibodies based out of California. Calico is known to provide custom, high-quality recombinant rabbit monoclonal antibodies developed for and used by biopharmaceutical and diagnostic companies.

Apparently, the deal would help to extend the industry leading position of Abcam in rabbit monoclonal antibodies, bringing forth a portfolio of ready-made CAL antibodies™ for immunohistochemistry (IHC), besides Calico’s customer development services. Calico has partnered with several leaders in diagnostics and biopharmaceuticals for creating custom products to be used in companion diagnostics.

The ready-made recombinant CAL antibodies™ from Calico for critical immuno-oncology targets would be available at both commercial and research scale through Abcam’s global commercial network. The company did not disclose financial terms regarding the deal, though it is projected to have minimal impact on earnings and revenue for fiscal year 2019. Announcement of the deal had reportedly propelled Abcam’s share prices in the U.K.

Calico CEO Jacinto Villanueva was quoted saying that Abcam is leading supplier of high-quality validated antibodies, supported by an innovative approach towards production as well as commercialization. This transaction will allow Calico to comprehensively support cancer research and associated diagnostics development, which is being carried out by its industry partners, Villanueva mentioned.

John Baker, Abcam’s SVP of Product Portfolio and Innovation, said acquiring Calico Biolabs is representative of the company’s execution of its strategy for providing highest-quality products to its customers in the diagnostic, biopharmaceutical and research sectors. He confirmed that Abcam has expanded its offerings of rabbit monoclonal for IHC by incorporating Calico’s custom services and product portfolio.

Baker stated that Abcam will be able to develop more products for its most important targets and that too faster. Bringing the Calico team to the Abcam family will boost Abcam’s mission to offer highest quality recombinant antibodies for research to its customers.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

GSK, Zymeworks expand partnership for bispecific antibody development
GSK, Zymeworks expand partnership for bispecific antibody development
By Nikita Chaurasia

GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases Zymeworks Inc, a clinical-stage biopharmaceutical company, has recently announced that GSK has extended its 2016 licensing ...

Vertex, Kymera join forces for developing protein degradation drugs
Vertex, Kymera join forces for developing protein degradation drugs
By Nikita Chaurasia

Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company Kymera Therapeutics and Vertex Pharmaceuticals Incorporated (VRTX) have reportedly announced that they are entering into a four-year rese...

Amazon plans job cuts as it deploys machines to pack orders
Amazon plans job cuts as it deploys machines to pack orders
By Nikita Chaurasia

Amazon is well known for its drive to automate as many segments of its business as possible. The American multinational technology company Amazon Inc. is reportedly planning to deploy machines to automate boxing up customer orders. The company has i...